

Trials of newer antidepressants for depressed children and/or adolescents  
Peter R Mansfield.  
March, 2007.

Drug	Name of trial if known to FDA in 2004 <sup>1</sup>	Number of subjects D=drug, P=placebo	Result according to Moreno et al 2007 <sup>2</sup>	Reason for reclassifying	Conclusion regarding result
<b>Published trials</b>					
Fluoxetine <sup>3</sup>	HCCJ	40 (D 20, P 20)	Negative		Negative
Fluoxetine <sup>4</sup>	X065	96 (D 48, P 48)	Positive	Published positive outcomes were not specified in the protocol. <sup>5</sup>	Negative
Fluoxetine <sup>6</sup>	HCJE	219 (D 109, P 110)	Positive	Negative after adjustment for baseline imbalance. <sup>7</sup>	Negative
Fluoxetine <sup>8</sup>		221* (D 109, P 112)	Negative		Negative
Paroxetine <sup>9</sup>	329	180** (D 93, P 87)	Positive	Published positive outcomes were not specified in the protocol. <sup>10</sup>	Negative
Paroxetine <sup>11</sup>	377	286 (D 187, P 99)	Negative		Negative
Paroxetine <sup>12</sup>	701	206 (D 104, P 102)	Negative		Negative
Citalopram <sup>13</sup>	CIT-MD-18	174 (D 89, P 85)	Positive	Protocol not publicly available	Possibly Positive
Citalopram <sup>14</sup>	94404	244 (D 124, P 120)	Negative		Negative
Escitalopram <sup>15</sup>		264 (D 131, P 133)	Negative		Negative
Venlafaxine <sup>16</sup>		40 (D 20, P 20)	Negative		Negative
Sertraline <sup>17</sup>	1001	188 (D 97, P 91)	Positive when combined but negative when analysed separately.		Negative
Sertraline <sup>18</sup>	1017	188 (D 92, P 96)			Negative
<b>Unpublished trials</b>					
Venlafaxine	382	165 (D 80, P 85)	Negative		Negative
Venlafaxine	394	196 (D 102, P 94)	Negative		Negative
Nefazodone***		195 (D 99, P 96)	Negative		Negative
Nefazodone	CN104141	206 (D 106, P 100)	Negative (Moreno were aware of only 2 nefazodone trials)		Negative
Nefazodone	CN104187	284 (D 190****, P 94)			Negative
Mirtazapine	45 Study 1	126 (D 82, P 44)	Negative		Negative
Mirtazapine	45 Study 2	133 (D 88, P 44)	Negative		Negative

\*Only includes patients randomized to fluoxetine or placebo.

\*\*Only includes patients randomized to paroxetine or placebo.

\*\*\*Presented at the 42nd Annual Meeting of NCDEU; 2002 Orlando, FL, USA. This may or may not be CN104141 or CN104187

\*\*\*\*Nefazodone was given in high dose (n=95) and low dose (n=95)

<sup>1</sup> Dubitsky GM. Review and evaluation of clinical data: Placebo-controlled antidepressant studies in pediatric patients. Bethesda: FDA 2004 August 6 <http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4065b1-08-TAB06-Dubitsky-Review.pdf>

<sup>2</sup> Moreno C, Arango C, Parellada M, Shaffer D, Bird H. Antidepressants in child and adolescent depression: where are the bugs? *Acta Psychiatr Scand.* 2007 Mar;115(3):184-95.

<sup>3</sup> Simeon JG, Dinicola VF, Ferguson HB, Copping W. Adolescent depression: a placebo-controlled fluoxetine treatment study and follow-up. *Prog Neuropsychopharmacol Biol Psychiatry* 1990;14:791-795.

<sup>4</sup> Emslie GJ, Rush AJ, Weinberg WA et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. *Arch Gen Psychiatry* 1997;54:1031-1037.

<sup>5</sup> Jureidini JN, Doecke CJ, Mansfield PR, Haby MM, Menkes DB, Tonkin AL. Efficacy and safety of antidepressants for children and adolescents. *BMJ* 2004;328:879-83

<sup>6</sup> Emslie GJ, Heiligenstein JH, Wagner KD et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. *J Am Acad Child Adolesc Psychiatry* 2002;41:1205-1215.

<sup>7</sup> Garland EJ. Facing the Evidence: Antidepressant Treatment in Children and Adolescents. *CMAJ*: 2004; 170: 489 – 491

- 
- <sup>8</sup> March J, Silva S, Petrycki S et al. Fluoxetine, cognitive behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. *JAMA* 2004;292:807–820.
- <sup>9</sup> Keller MB, Ryan ND, Strober M et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. *J Am Acad Child Adolesc Psychiatry* 2001;40:762–772.
- <sup>10</sup> GlaxoSmithKline. Paroxetine and pediatric and adolescent patients. [www.gsk.com/media/paroxetine.htm](http://www.gsk.com/media/paroxetine.htm) (accessed 23 February 2007)
- <sup>11</sup> Berard R, Fong R, Carpenter DJ, Thomason C, Wilkinson C. An international, multicenter, placebo-controlled trial of paroxetine in adolescents with major depressive disorder. *J Child Adolesc Psychopharmacol* 2006;16:59–75.
- <sup>12</sup> Emslie GJ, Wagner KD, Kutcher S et al. Paroxetine treatment in children and adolescents with major depressive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. *J Am Acad Child Adolesc Psychiatry* 2006;45:709–719.
- <sup>13</sup> Wagner KD, Robb AS, Findling RL et al. A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. *Am J Psychiatry* 2004;161:1079–1083.
- <sup>14</sup> Von Knorring AL, Olsson GI, Thomsen PH, Lemming OM, Hulten A. A randomized, double-blind, placebo-controlled study of citalopram in adolescents with major depressive disorder. *J Clin Psychopharmacol* 2006;26: 311–315.
- <sup>15</sup> Wagner KD, Jonas J, Findling RL, Ventura D, Saikali K. A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. *J Am Acad Child Adolesc Psychiatry* 2006;45:280–288.
- <sup>16</sup> Mandoki MW, Tapia MR, Tapia MA, Sumner GS, Parker JL. Venlafaxine in the treatment of children and adolescents with major depression. *Psychopharmacol Bull* 1997;33:149–154.
- <sup>17</sup> Wagner KD, Ambrosini P, Rynn M et al. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. *JAMA* 2003;290:1033–1041.
- <sup>18</sup> Wagner KD, Ambrosini P, Rynn M et al. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. *JAMA* 2003;290:1033–1041.